1887

Abstract

Adenoviruses (Ads) are non-enveloped DNA viruses that have been extensively studied and used as vectors for gene therapy and several potential vaccines. There are 57 Ad serotypes in seven species (A–G), and Ad neutralizing antibody (NAb) titres can vary by serotype and geographical location. Until now serotype- and species-specific antibodies have been detected by neutralization or haemagglutination inhibition assays. These expensive and cumbersome methods of adenovirus typing have mainly been used in epidemiological studies. Our prior work demonstrated that NAbs against the fiber protein are commonly generated during natural Ad infection in humans and the trimeric knob is preferentially recognized by fiber-induced NAbs. In this study, we expressed nine trimeric knob proteins from representative Ad serotypes of human Ad (HAdV)-A–F in and found no cross-reactivity of these recombinant proteins with rabbit hyperimmune sera (among HAdV-A–F or within HAdV-C). Results of the ELISA based on Ad2 and Ad5 (both HAdV-C) knob proteins were consistent with those of neutralization assays, indicating that the trimeric knob protein would be a good candidate antigen for detecting Ad serotype-specific NAbs in sera from naturally infected subjects. We also demonstrated the primary seroepidemiology of nine Ad serotypes in 274 children using the knob-based ELISA. These results have potential implications for epidemiology of Ad serotypes and future development of Ad-based vaccines and gene therapy.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.064832-0
2014-07-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/7/1564.html?itemId=/content/journal/jgv/10.1099/vir.0.064832-0&mimeType=html&fmt=ahah

References

  1. Abbink P., Lemckert A. A., Ewald B. A., Lynch D. M., Denholtz M., Smits S., Holterman L., Damen I., Vogels R.. & other authors ( 2007; ). Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. . J Virol 81:, 4654–4663. [CrossRef] [PubMed]
    [Google Scholar]
  2. Appaiahgari M. B., Saini M., Rauthan M., Jyoti, Vrati S.. ( 2006; ). Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. . Microbes Infect 8:, 92–104. [CrossRef] [PubMed]
    [Google Scholar]
  3. Appaiahgari M. B., Pandey R. M., Vrati S.. ( 2007; ). Seroprevalence of neutralizing antibodies to adenovirus type 5 among children in India: implications for recombinant adenovirus-based vaccines. . Clin Vaccine Immunol 14:, 1053–1055. [CrossRef] [PubMed]
    [Google Scholar]
  4. Arnberg N., Edlund K., Kidd A. H., Wadell G.. ( 2000; ). Adenovirus type 37 uses sialic acid as a cellular receptor. . J Virol 74:, 42–48. [CrossRef] [PubMed]
    [Google Scholar]
  5. Aste-Amézaga M., Bett A. J., Wang F., Casimiro D. R., Antonello J. M., Patel D. K., Dell E. C., Franlin L. L., Dougherty N. M.. & other authors ( 2004; ). Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. . Hum Gene Ther 15:, 293–304. [CrossRef] [PubMed]
    [Google Scholar]
  6. Badger G. F., Curtiss C., Dingle J. H., Ginsberg H. S., Gold E., Jordan W. S. Jr. ( 1956; ). A study of illness in a group of Cleveland families. X. The occurrence of adenovirus infections. . Am J Hyg 64:, 336–348.[PubMed]
    [Google Scholar]
  7. Barouch D. H., Pau M. G., Custers J. H., Koudstaal W., Kostense S., Havenga M. J., Truitt D. M., Sumida S. M., Kishko M. G.. & other authors ( 2004; ). Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. . J Immunol 172:, 6290–6297. [CrossRef] [PubMed]
    [Google Scholar]
  8. Barouch D. H., Kik S. V., Weverling G. J., Dilan R., King S. L., Maxfield L. F., Clark S., Ng’ang’a D., Brandariz K. L.. & other authors ( 2011; ). International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. . Vaccine 29:, 5203–5209. [CrossRef] [PubMed]
    [Google Scholar]
  9. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W.. ( 1997; ). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. . Science 275:, 1320–1323. [CrossRef] [PubMed]
    [Google Scholar]
  10. Berk A.. ( 2007; ). Adenoviridae: The viruses and their replication. . In Fields virology, , 5th edn., pp. 2355–2394. Edited by Knipe D. M. Knipe et al.. Philadelphia:: Lippincott Williams & Wilkins;.
    [Google Scholar]
  11. Brandt C. D., Kim H. W., Vargosko A. J., Jeffries B. C., Arrobio J. O., Rindge B., Parrott R. H., Chanock R. M.. ( 1969; ). Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to serologic type and illness syndrome. . Am J Epidemiol 90:, 484–500.[PubMed]
    [Google Scholar]
  12. Buchbinder S. P., Mehrotra D. V., Duerr A., Fitzgerald D. W., Mogg R., Li D., Gilbert P. B., Lama J. R., Marmor M.. & other authors ( 2008; ). Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. . Lancet 372:, 1881–1893. [CrossRef] [PubMed]
    [Google Scholar]
  13. Carr M. J., Kajon A. E., Lu X., Dunford L., O’Reilly P., Holder P., De Gascun C. F., Coughlan S., Connell J.. & other authors ( 2011; ). Deaths associated with human adenovirus-14p1 infections, Europe, 2009–2010. . Emerg Infect Dis 17:, 1402–1408. [CrossRef] [PubMed]
    [Google Scholar]
  14. Casimiro D. R., Chen L., Fu T. M., Evans R. K., Caulfield M. J., Davies M. E., Tang A., Chen M., Huang L.. & other authors ( 2003; ). Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. . J Virol 77:, 6305–6313. [CrossRef] [PubMed]
    [Google Scholar]
  15. Cheng C., Gall J. G. D., Nason M., King C. R., Koup R. A., Roederer M., McElrath M. J., Morgan C. A., Churchyard G.. & other authors ( 2010; ). Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. . J Virol 84:, 630–638. [CrossRef] [PubMed]
    [Google Scholar]
  16. Farina S. F., Gao G. P., Xiang Z. Q., Rux J. J., Burnett R. M., Alvira M. R., Marsh J., Ertl H. C., Wilson J. M.. ( 2001; ). Replication-defective vector based on a chimpanzee adenovirus. . J Virol 75:, 11603–11613. [CrossRef] [PubMed]
    [Google Scholar]
  17. Fitzgerald J. C., Gao G. P., Reyes-Sandoval A., Pavlakis G. N., Xiang Z. Q., Wlazlo A. P., Giles-Davis W., Wilson J. M., Ertl H. C.. ( 2003; ). A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. . J Immunol 170:, 1416–1422. [CrossRef] [PubMed]
    [Google Scholar]
  18. Gahéry-Ségard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J. G.. ( 1998; ). Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. . J Virol 72:, 2388–2397.[PubMed]
    [Google Scholar]
  19. Havenga M. J. E., Lemckert A. A. C., Ophorst O. J. A. E., van Meijer M., Germeraad W. T. V., Grimbergen J., van Den Doel M. A., Vogels R., van Deutekom J.. & other authors ( 2002; ). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. . J Virol 76:, 4612–4620. [CrossRef] [PubMed]
    [Google Scholar]
  20. Hierholzer J. C., Stone Y. O., Broderson J. R.. ( 1991; ). Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera. . Arch Virol 121:, 179–197. [CrossRef] [PubMed]
    [Google Scholar]
  21. Hung-Yueh Y., Pieniazek N., Pieniazek D., Gelderblom H., Luftig R. B.. ( 1994; ). Human adenovirus type 41 contains two fibers. . Virus Res 33:, 179–198. [CrossRef] [PubMed]
    [Google Scholar]
  22. Khare R., Chen C. Y., Weaver E. A., Barry M. A.. ( 2011; ). Advances and future challenges in adenoviral vector pharmacology and targeting. . Curr Gene Ther 11:, 241–258. [CrossRef] [PubMed]
    [Google Scholar]
  23. Kolavic-Gray S. A., Binn L. N., Sanchez J. L., Cersovsky S. B., Polyak C. S., Mitchell-Raymundo F., Asher L. V., Vaughn D. W., Feighner B. H., Innis B. L.. ( 2002; ). Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies. . Clin Infect Dis 35:, 808–818. [CrossRef] [PubMed]
    [Google Scholar]
  24. Marttila M., Persson D., Gustafsson D., Liszewski M. K., Atkinson J. P., Wadell G., Arnberg N.. ( 2005; ). CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. . J Virol 79:, 14429–14436. [CrossRef] [PubMed]
    [Google Scholar]
  25. Mast T. C., Kierstead L., Gupta S. B., Nikas A. A., Kallas E. G., Novitsky V., Mbewe B., Pitisuttithum P., Schechter M.. & other authors ( 2010; ). International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. . Vaccine 28:, 950–957. [CrossRef] [PubMed]
    [Google Scholar]
  26. Norrby E.. ( 1969; ). The structural and functional diversity of Adenovirus capsid components. . J Gen Virol 5:, 221–236. [CrossRef] [PubMed]
    [Google Scholar]
  27. Pereira H. G.. ( 1959; ). Adenoviruses. . Br Med Bull 15:, 225–230.[PubMed]
    [Google Scholar]
  28. Piedra P. A., Poveda G. A., Ramsey B., McCoy K., Hiatt P. W.. ( 1998; ). Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors. . Pediatrics 101:, 1013–1019. [CrossRef] [PubMed]
    [Google Scholar]
  29. Priddy F. H., Brown D., Kublin J., Monahan K., Wright D. P., Lalezari J., Santiago S., Marmor M., Lally M.. & other authors ( 2008; ). Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. . Clin Infect Dis 46:, 1769–1781. [CrossRef] [PubMed]
    [Google Scholar]
  30. Roberts D. M., Nanda A., Havenga M. J., Abbink P., Lynch D. M., Ewald B. A., Liu J., Thorner A. R., Swanson P. E.. & other authors ( 2006; ). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. . Nature 441:, 239–243. [CrossRef] [PubMed]
    [Google Scholar]
  31. Rux J. J., Burnett R. M.. ( 2000; ). Type-specific epitope locations revealed by X-ray crystallographic study of adenovirus type 5 hexon. . Mol Ther 1:, 18–30. [CrossRef] [PubMed]
    [Google Scholar]
  32. Sanchez J. L., Binn L. N., Innis B. L., Reynolds R. D., Lee T., Mitchell-Raymundo F., Craig S. C., Marquez J. P., Shepherd G. A.. & other authors ( 2001; ). Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults. . J Med Virol 65:, 710–718. [CrossRef] [PubMed]
    [Google Scholar]
  33. Seiradake E., Lortat-Jacob H., Billet O., Kremer E. J., Cusack S.. ( 2006; ). Structural and mutational analysis of human Ad37 and canine adenovirus 2 fiber heads in complex with the D1 domain of coxsackie and adenovirus receptor. . J Biol Chem 281:, 33704–33716. [CrossRef] [PubMed]
    [Google Scholar]
  34. Sprangers M. C., Lakhai W., Koudstaal W., Verhoeven M., Koel B. F., Vogels R., Goudsmit J., Havenga M. J., Kostense S.. ( 2003; ). Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. . J Clin Microbiol 41:, 5046–5052. [CrossRef] [PubMed]
    [Google Scholar]
  35. Takeuchi S., Itoh N., Uchio E., Aoki K., Ohno S.. ( 1999; ). Serotyping of adenoviruses on conjunctival scrapings by PCR and sequence analysis. . J Clin Microbiol 37:, 1839–1845.[PubMed]
    [Google Scholar]
  36. Vogels R., Zuijdgeest D., van Rijnsoever R., Hartkoorn E., Damen I., de Béthune M. P., Kostense S., Penders G., Helmus N.. & other authors ( 2003; ). Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. . J Virol 77:, 8263–8271. [CrossRef] [PubMed]
    [Google Scholar]
  37. Walsh M. P., Seto J., Liu E. B., Dehghan S., Hudson N. R., Lukashev A. N., Ivanova O., Chodosh J., Dyer D. W.. & other authors ( 2011; ). Computational analysis of two species C human adenoviruses provides evidence of a novel virus. . J Clin Microbiol 49:, 3482–3490. [CrossRef] [PubMed]
    [Google Scholar]
  38. Wang H., Li Z. Y., Liu Y., Persson J., Beyer I., Möller T., Koyuncu D., Drescher M. R., Strauss R.. & other authors ( 2011; ). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. . Nat Med 17:, 96–104. [CrossRef] [PubMed]
    [Google Scholar]
  39. Weinberg A., Fink M. C., Takimoto S., Ishida M. A., Souza M. C.. ( 1989; ). Enzyme linked immunosorbent assay: determination of anti-adenovirus antibodies in an infant population. . Rev Inst Med Trop Sao Paulo 31:, 336–340. [CrossRef] [PubMed]
    [Google Scholar]
  40. Yu B., Wang C., Dong J., Zhang M., Zhang H., Wu J., Wu Y., Kong W., Yu X.. ( 2012a; ). Chimeric hexon HVRs protein reflects partial function of adenovirus. . Biochem Biophys Res Commun 421:, 170–176. [CrossRef] [PubMed]
    [Google Scholar]
  41. Yu B., Zhou Y., Wu H., Wang Z., Zhan Y., Feng X., Geng R., Wu Y., Kong W., Yu X.. ( 2012b; ). Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. . J Med Virol 84:, 1408–1414. [CrossRef] [PubMed]
    [Google Scholar]
  42. Yu B., Dong J., Wang C., Zhan Y., Zhang H., Wu J., Kong W., Yu X.. ( 2013; ). Characteristics of neutralizing antibodies to adenovirus capsid proteins in human and animal sera. . Virology 437:, 118–123. [CrossRef] [PubMed]
    [Google Scholar]
  43. Zhang Y., Bergelson J. M.. ( 2005; ). Adenovirus receptors. . J Virol 79:, 12125–12131. [CrossRef] [PubMed]
    [Google Scholar]
  44. Zhang Q., Seto D., Cao B., Zhao S., Wan C.. ( 2012; ). Genome sequence of human adenovirus type 55, a re-emergent acute respiratory disease pathogen in China. . J Virol 86:, 12441–12442. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.064832-0
Loading
/content/journal/jgv/10.1099/vir.0.064832-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error